DelRicht Research

What DelRicht Research does

DelRicht Research is a U.S.-based site management organization (SMO) that operates a network of clinical research sites embedded directly within partner physicians' practices. Rather than running standalone research clinics, the company co-locates dedicated research teams inside active high-volume physician offices across 20+ U.S. cities, giving its sponsors and CRO partners direct access to existing patient populations for recruitment. Its core offering is professional services for clinical trial execution: patient identification and enrollment, study visit conduct, data collection, and regulatory-compliant documentation, delivered through embedded investigator teams backed by a centralized operations function.

The company serves two primary customer segments: pharmaceutical sponsors (including Pfizer, Moderna, Lilly, Novartis, AbbVie, AstraZeneca, GSK, Sanofi, and others) and contract research organizations (including IQVIA, Parexel, Syneos Health, Fortrea, Medpace, and PPD). Revenue is generated through project-based contracts tied to specific trial protocols and enrollment milestones, with pricing negotiated under master service agreements that are not publicly disclosed. DelRicht claims a clean regulatory record with no FDA Form 483 observations across its sites and has publicly supported named FDA approvals including UCB's BIMZELX in psoriasis and Arcutis's ZORYVE and VTAMA.

The company's go-to-market is enterprise B2B: a business development team targets sponsors and CROs for new trial awards, while patient recruitment is handled at the site level by site coordinators using existing physician-relationship-based databases and community outreach. DelRicht's stated competitive advantages are its embedded access to active patient populations, expedited trial start-up timelines, inspection-ready data quality, and a 45%+ average diversity rate across its site network. The company was founded in 2014, is privately held, and is headquartered in New Orleans, Louisiana.

Name

DelRicht Research

Legal name

DelRicht Research

Website

https://delrichtresearch.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

DelRicht Research is a U.S. site management organization operating embedded clinical trial sites within partner physicians' practices across 20+ cities, conducting studies for pharmaceutical sponsors and CROs including Pfizer, Lilly, IQVIA, and Parexel.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Trial Patient Recruitment & Retention (HLAGACAD), Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Clinical trial services
• Site management organization
• Patient recruitment
• Clinical research sites
• Embedded research network

Headquarters

HQ city

New Orleans

HQ country

United States

HQ region

North America

Offices20 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Trial Services: DelRicht Research generates revenue by conducting clinical trials on behalf of pharmaceutical sponsors and CROs. As a site network, they receive compensation for patient enrollment, study execution, and data collection services. Revenue is project-based, tied to specific trial protocols and enrollment milestones.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

DelRicht Research operates a network of integrated research sites embedded within physician practices across the United States, conducting clinical trials on behalf of pharmaceutical sponsors and CROs. Services include patient enrollment, study execution, regulatory-compliant data collection, and trial management, leveraging existing high-volume patient populations at investigator clinics. Revenue is generated per protocol under multi-year contract research agreements with sponsors and CROs.

Product overview

DelRicht Research is an integrated network of investigational research sites embedded within physicians' practices, offering clinical trial services as a unified platform rather than discrete products. Their core offering consists of dedicated research teams supported by centralized operations to help pharmaceutical sponsors and CROs advance clinical trials. The company manages sites across the United States with investigators representing various medical specialties.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Site Services End-to-end clinical trial execution services delivered through a network of research sites embedded in physician practices, including patient enrollment, study conduct, data collection, and regulatory-compliant data delivery for pharmaceutical sponsors and CROs.

Quantifiable outcome

• 267% of enrollment target achieved in Phase 2 obesity & T2DM trial
• +4 more outcomes

Named customers16 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

27 partnerships are on record, tiered minor.

• Vyne TherapeuticsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Dermavant SciencesminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• LundbeckminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Novo NordiskminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• GenentechminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Esperion TherapeuticsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• ShionogiminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Biohaven PharmaceuticalsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Menlo TherapeuticsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• IncyteminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• AthenexminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Sucampo PharmaceuticalsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Worldwide Clinical TrialsminorStrategic or Co-development PartnerCRO engaged with DelRicht Research for clinical trial execution services.
• Urovant SciencesminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Evofem BiosciencesminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Botanix PharmaceuticalsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Satsuma PharmaceuticalsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Sol-Gel TechnologiesminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• IndegeneminorStrategic or Co-development PartnerCRO/Healthcare services partner engaged with DelRicht Research for clinical trial execution services.
• Swing TherapeuticsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Teva PharmaceuticalsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• UCBminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services. DelRicht supported UCB's BIMZELX FDA approval in psoriasis.
• Allergan (AbbVie)minorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Arcutis BiotherapeuticsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services. DelRicht supported Arcutis's Zoryve and VTAMA FDA approvals.
• Premier ResearchminorStrategic or Co-development PartnerCRO engaged with DelRicht Research for clinical trial execution services.
• OtonomyminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.
• Endo PharmaceuticalsminorStrategic or Co-development PartnerPharmaceutical sponsor engaged with DelRicht Research for clinical trial execution services.

Scale indicators10 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Velocity Clinical Research: One of the largest integrated SMO/site networks in the US, operating dozens of embedded research sites across multiple therapeutic areas. Directly comparable to DelRicht in business model, customer base (pharma sponsors and CROs), and emphasis on rapid enrollment.
• Meridian Clinical Research: Privately-held US site network with embedded investigator sites spanning therapeutic areas including vaccines, dermatology, and metabolic disease. Highly comparable to DelRicht in scale, operating model, and sponsor mix.
• Elligo Health Research: SMO that operates a network of community-based research sites (Goes Direct® model) leveraging existing physician practices — structurally analogous to DelRicht's embedded-clinic approach with a technology overlay.
• Centricity Research: Multi-site clinical research organization with embedded investigator sites across North America. Comparable therapeutic breadth, sponsor relationships, and emphasis on community-based recruitment.
• Optimus Clinical Research (Optimal Research): Specialty SMO focused on dermatology and other therapeutic areas, operating a network of investigator sites. Highly comparable given DelRicht's dermatology concentration and similar embedded-site model.

Broad incumbents

• IQVIA: Largest global CRO with an extensive site network and site-management services. A direct customer of DelRicht (CRO partner) that also competes for the same embedded-site niche via its own SMO assets.
• Medpace: Mid-to-large global CRO with significant in-house site coordination capabilities and preferred-site relationships. Listed as a CRO customer of DelRicht, indicating overlap in the same sponsor-CRO-site ecosystem.
• Syneos Health: Global CRO with site-management offerings, listed as a CRO customer of DelRicht. Comparable as a broader incumbent that competes for site-allocation and protocol-execution work.
• Worldwide Clinical Trials: Mid-sized global CRO with site-services capabilities. Both a CRO customer and a competitor to DelRicht in the same embedded-site, sponsor-direct segment.

Emerging players

• Science 37: Technology-enabled decentralized clinical trial operator that represents an emerging alternative to traditional embedded-site networks. Comparable in serving the same pharma sponsors but differentiated by remote/decentralized delivery models.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/delrichtresearch
• Instagraminstagram.com/delricht_research
• Xx.com/delricht
• LinkedInlinkedin.com/company/delricht-clinical-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DelRicht Research